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Hepatitis C virus (HCV) proteins appear to play an important role in IFN-resistance, but the molecular mechanism remains unclear. To clarify
the mechanism in HCV replicon RNA harboring Huh-7 cells (Huh-9-13), we isolated cellular clones with impaired IFNα-sensitivity. Huh-9-13
was cultured for approximately 2 months in the presence of IFNα, and 4 IFNα-resistant cell clones showing significant resistances were obtained.
When total RNA from clones was introduced into Huh-7 cells, the transfected cells also exhibited IFNα-resistance. Although no common
mutations were present, mutations in NS3 and NS5A regions were accumulated. Transactivation of IFNα and IFNα-stimulated Stat-1 phos-
phorylation were reduced, and the elimination of HCV replicon RNA from the clones restored the IFNα signaling. These results suggest that the
mutations in the HCV replicon RNA, at least in part, cause an inhibition of IFN signaling and are important for acquisition of IFNα resistance in
Huh-9-13.
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Hepatitis C virus (HCV) is the major cause of post-transfusion
non-A non-B hepatitis. Approximately 170 million individuals
worldwide were estimated to be infected with HCV (Alter, 1997).
It has been suggested that the development of liver cirrhosis and
hepatocellular carcinoma are consequences of chronic infection
with HCV (Hijikata et al., 1993b; Tong et al., 1995).
HCV, a member of the Flaviviridae family, has a single-
stranded positive-sense linear RNA genome of about 9.5 kb
(Hijikata et al., 1991; Kato et al., 1990; Takamizawa et al.,
1991). The RNA encodes a single precursor polyprotein of
approximately 3010 amino acids (Choo et al., 1991; Okamoto
et al., 1991, 1992) that is co- and post-translationally cleaved to⁎ Corresponding author. Central Pharmaceutical Research Institute, Japan
Tobacco Inc., Takatsuki, Osaka 569-1125, Japan. Fax: +81 726 81 9783.
E-mail address: toru.noguchi@ims.jti.co.jp (T. Noguchi).
1 Current address: Center for Integrated Medical Research, Keio University,
Tokyo, Shinjuku 160-8582, Japan.
0042-6822/$ - see front matter © 2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2008.02.009produce individual structural (Core, E1, E2) and nonstructural
proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) by both
host and viral proteases (Hijikata et al., 1993a,b; Houghton,
1996).
The cell line Huh-9-13, in which the HCV subgenome can
self-replicate, was established by R. Bartenschlager's group (Lo-
hmann et al., 1999). The HCV subgenomic RNA consists of the
entire nonstructural coding region of the Con1 strain of the HCV
genome, except for the neomycin-resistant gene. This cell line
provides significant information for understanding the replication
of the HCV genome and is useful as a powerful screening tool for
developing anti-HCV drugs (Bartenschlager et al., 2000, 2001).
Interferon alpha (IFNα) is widely used for the treatment of
patients with chronic HCV infection; however, the effectiveness
of IFNα, especially in genotype 1b, is low at only about 20–30%
(Lindsay, 1997), although combination therapy with Ribavirin
improves treatment outcomes (up to 50–60%) (McHutchison
et al., 1998). According to reports of epidemiologic analysis
conducted in Japan, IFN treatment outcomes are related with
mutations within a 40 amino acid sequence in NS5A (amino acid
Fig. 1. An outline of the process used for isolation of replicon cells showing IFNα-resistance. Total RNA transfection derived from replicons to naive Huh-7 cells was
performed using DMRIE-C reagent (Invitrogen).
Fig. 2. Reactivity for IFNα in established IFNα-resistant replicon cells (#6, #8,
#9, and #305) and original replicon cells (Huh-9-13). The cells were treated with
IFNα for 48 h, and the amount of HCV RNAwas measured by quantitative RT-
PCR. (A) EC50 value (IU/mL) of IFNα in each replicon and fold reduction of the
value compared to original replicon (Huh-9-13). (B) Change in copy number of
HCV RNA in original and IFNα-resistant replicons by IFNα treatment. These
experiments were performed in triplicate and mean values are shown.
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HCV-J polyprotein) called the interferon sensitivity determining
region (ISDR) (Enomoto et al., 1996). However, it is not clear
how NS5A functionally interacts with IFN signals. Alterna-
tively, NS5A is shown to inhibit the activity of double-stranded
RNA (dsRNA)-activated protein kinase (PKR) and 2′-5′-
oligoadenylate synthetase (2′-5′-OAS) induced by IFNα (Gale
et al., 1997; Noguchi et al., 2001; Taguchi et al., 2004).
Recently, Meylan et al. and other groups reported that HCV-
NS3-4A protease cleaved Cardif (Meylan et al., 2005) (also
designated as VISA (Xu et al., 2005), MAVS (Seth et al., 2005),
IPS-1 (Kawai et al., 2005)) and suppressed IFN production
through RIG-I signaling. Cardif interacts with RIG-I (Yoneyama
et al., 2004) mediated through CARD domains in both moleculesFig. 3. Western blot analysis of the established IFNα-resistant replicon cells (#6,
#8, #9, and #305) and original replicon cells (Huh-9-13). Expression of β-actin
was used as an internal control of cellular protein in the replicon cells. Each cell
line was inoculated on a 60-mm plate at 3×105 cells/well. Twenty-four hours
after inoculation, the cells were lysed with SDS sample buffer. Total proteins
were subjected to a 2/15% SDS gradient gel, and were subsequently immu-
noblotted by NS3 (A), NS5A (B), NS5B (C), and β-actin (D) antibody.
Fig. 4. Transactivation of ISRE in IFNα-resistant replicon cell lines (#8 and
#305), original replicon (Huh-9-13), and parental Huh-7 cells by reporter gene
(pISRE/Luc) analysis. The cells were stimulated with 1000 IU/mL of IFNα for
24 h after transfection of reporter plasmid DNA. White bars show control (no
addition of IFNα) luciferase activity, and black bars show the activity under
IFNα stimulation. Values of luciferase activity by IFNα stimulation relative to
those of untreated cells are shown below the panel as ‘fold induction’.
426 T. Noguchi et al. / Virology 375 (2008) 424–432in a dsRNA-dependent manner, and transduce IFN production
signals through the activation of nuclear factor κB (NFκB) and
interferon regulatory factor 3 (IRF-3).
Despite bearing an HCV-1b genotype-derived replicon with
mutations in ISDR, the replicon cells do not show resistances to
IFN (Frese et al., 2002; Guo et al., 2001, 2004). Concerning this
point, some reports regarding IFN-resistance acquisition and
analysis of this property in the replicon cells (Namba et al., 2004;Fig. 5. (A) Change in phosphorylation of Stat-1 in IFNα-resistant replicon cell
lines (#8 and #305), original replicon (Huh-9-13) and parental Huh-7 cell.
Phosphorylation of Stat-1 was analyzed by western blot analysis using anti-
phospho-Stat-1 (Tyr701) antibody. The cells were cultured in medium with or
without 500 IU/mL of IFNα for 30 min. Upper panel represents a phospho-Stat-
1 (Tyr701) and lower panel shows a Stat-1. Western blot analysis was performed
as described in Materials and methods. (B) Change in phosphorylation of Stat-1
in Huh-7 cells maintained in the presence or absence of IFNα (10 IU/mL) for
4 weeks. Upper panel represents a phospho-Stat-1 (Tyr701), middle panel shows
a Stat-1 and lower panel shows a β-actin. Phosphorylation of Stat-1 in these cells
was examined as described above.Sumpter et al., 2004; Zhu et al., 2005) showed involvement of
various factors such as viral and/or host gene alterations par-
ticipating in IFNα-resistance in replicon cells.
Here, we isolated IFNα-resistant clones of the HCV subge-
nome with accumulated mutations, especially in NS3 and NS5A
regions. We observed impairment of phosphorylation of Stat-1 in
cells bearing the IFNα-resistant HCV replicon. Our findings sug-
gest that NS5A contributes to the acquisition of IFNα-resistant
phenotype in HCV replicon cells.
Results
Establishment of IFNα-resistant replicon cell lines
HCV replicon cells were cultured for approximately 1 month
in the presence of 10 IU/mL IFNα. HCV RNA titer decreased
during the culture; however, the appearance of cells less sen-
sitive to IFNα during prolonged culture was observed by quan-
titative RT-PCR. The resistant cells were then cloned by limiting
dilution. Three clones (Fig. 1: #6, #8, and #9) were obtained,
and mixed pools of these resistant cells were further selected in
the presence of 30 IU/mL IFNα for another 4 weeks. After
confirming decreased sensitivity to IFNα at this dose, the cloneFig. 6. Reactivity for IFNα in the Huh-7 cells, #305/Huh-7, transfected with
total RNA of #305 replicon cells and in the Huh-7 cells, Huh-9-13/Huh-7,
transfected with total RNA of original replicon cells (Huh-9-13). These trans-
fected cells were selected with G418 in the absence of IFNα. The amount of
HCV RNA was analyzed by quantitative RT-PCR, as described in Fig. 2. (A)
EC50 value (IU/mL) of IFNα in Huh-9-13/Huh-7 and #305/Huh-7. (B) Change
in copy number of HCV RNA in Huh-9-13/Huh-7 and #305/Huh-7 by IFNα
treatment. These experiments were performed in triplicate and mean values are
shown.
Fig. 7. Phosphorylation of Stat-1 in #305/Huh-7 and Huh-9-13/Huh-7 described
in Fig. 6. The experiment was performed as described in Fig. 5. Each panel
shows (A) phospho-Stat-1 (Tyr701), (B) Stat-1, and (C) β-actin. (Lanes 1 and 2)
Huh-7 cells transfected with IFNα-resistant replicon (#305) total RNA (#305/
Huh-7). (Lanes 3 and 4) Huh-7 cells transfected with original replicon (Huh-9-
13) total RNA (Huh-9-13/Huh-7).
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Sensitivities of these clones to IFNα are shown in Fig. 2. The
basal HCV RNA levels in these cells (#6, #8, #9, and #305)
were almost equal to that in the original replicon cells (Huh-9-
13). The EC50 value of IFNα for the original replicon (Huh-9-
13) was 0.7 IU/mL, compared to 6.9 IU/mL, 6.7 IU/mL,
10.2 IU/mL, and 99.2 IU/mL for resistant clones #6, #8, #9, and
#305, respectively. These results demonstrate that sensitivity to
IFNα based on EC50 value decreased 9 to 135-fold in the IFNα-
resistant clones.
Characterization of IFNα-resistant replicon cell lines
First, expression of HCV NS proteins (NS3, NS5A, and
NS5B) in IFNα-resistant replicon cell lines (#6, #8, #9, and #305)
was analyzed by western blot. We detected expression of all the
NS proteins in these cell lines as well as in original replicon cell
(Huh-9-13) at almost at the same levels, although the levels of
NS5A and NS5B in clone #6 were slightly low (Fig. 3). In-
terestingly, only clone #305 exhibited a different migration ofFig. 8. The amino acid sequence deduced from nucleotide sequence in IFNα-resistan
sequencing method. Arrows indicate the amino acid substitutions that were detected o
numbering of amino acids was referred to that of complete polyprotein of the isolatNS5A, corresponding to the size of hyper-phosphorylated form
(p58) in addition to the size of basal phosphorylated form (p56).
To analyze the change in IFNα signal transduction in two
representative IFNα-resistant replicon cell lines (#8 and #305),
we carried out a reporter gene assay using a firefly luciferase
gene fused with three repeats of an ISG15-type IFN-stimulated
responsive element (ISRE) as a reporter construct (pISRE/Luc).
After transfection of pISRE/Luc to these replicon cells, the cells
were stimulated with 1000 IU/mL of IFNα for 24 h. As shown
in Fig. 4, the transactivation by IFNα in original replicon cells
(Huh-9-13) was slightly reduced compared with that of parental
cell line Huh-7 (Huh-7, 9.3-fold; Huh-9-13, 6.4-fold). Lucifer-
ase activity of #8 and #305 was more diminished than that of
Huh-9-13 (#8, 3.6-fold; #305, 1.9-fold). The extent of decline of
transactivation by IFNα treatment in these resistant replicon cell
lines was dependent on the extent of IFNα-resistance, as
quantified by RT-PCR (Fig. 2). It is suggested that the genetic
alteration in HCV replicon RNA confers on IFNα-resistance in
these cell lines.
In relation to the reporter gene analysis, JAK-STAT pathway
activated by type I IFN was analyzed in IFNα-resistant repli-
cons containing cells (#8 and #305). Phosphorylation of Stat-1,
one of the important molecules in the JAK-STAT signal trans-
duction pathway, was lowered in original replicon cells (Huh-9-
13) compared with that in parental Huh-7 (Fig. 5A). However,
severely impaired phosphorylation of Stat-1 was observed in the
IFNα-resistant replicons containing cells (#8 and #305) com-
pared with original replicon cells (Huh-9-13) (Fig. 5A). Fur-
thermore, phosphorylation of Stat-1 was also decreased in #305
containing cells maintained in the absence of IFNα for 4 weeks,
and the degree of decrease of Stat-1 phosphorylation was almost
equal to that maintained in the presence of IFNα (data not
shown). In contrast to these observations, Huh-7 cells, the
parental cell of Huh-9-13 that was maintained in the presence
of IFNα for 4 weeks did not show the significant alteration of
Stat-1 phosphorylation compared with that maintained in the
absence of IFNα (Fig. 5B). These results suggest that reduction
of phosphorylation of Stat-1 in these IFNα-resistant replicon
cell lines is caused by alteration of HCV replicon RNA and it
may correlate with suppression of transcription from the re-
porter gene (Fig. 4).t replicon cells. The nucleotide sequence was determined by an RT-PCR direct
nly in IFNα-resistant replicons compared with original replicon (Huh-9-13). The
e.
Fig. 10. Phosphorylation of Stat-1 (Tyr701) in ‘cured cells’. Phosphorylation of
Stat-1 (Tyr701) (A) by IFNα stimulation was investigated by western blot
analysis. Stat-1 (B) and β-actin (C) were also analyzed. IFNα stimulation and
western blot analysis were performed as described in Fig. 5.
428 T. Noguchi et al. / Virology 375 (2008) 424–432HCV replicon RNA confers IFNα-resistance
To confirm the role of HCV subgenomic RNA from clone
#305 for acquisition of IFNα-resistance, total RNA was ex-
tracted from the cells and transfected to naive Huh-7 cells. The
transfected cells were selected with G418 in the absence of
IFNα. HCV negative-stranded replicon RNA, replication inter-
mediate, and HCV NS proteins (NS3, NS5A and NS5B) were
detected in the cells (data not shown).
Concerning the cells transfected with total RNA from IFNα-
resistant #305 cell (#305/Huh-7) or the cells transfected with
total RNA from original Huh-9-13 replicon cell (Huh-9-13/
Huh-7), IFNα-sensitivity (EC50) was analyzed (Fig. 6). IFNα-
sensitivity (EC50) of the Huh-9-13/Huh-7 showed 0.7 IU/mL,
whereas the #305/Huh-7 showed 4.1 IU/mL. EC50 values of the
Huh-7 cells bearing IFNα-resistant replicon derived from clone
#305 were approximately 6-fold higher than that of Huh-7 cells
bearing the original replicon. Although IFNα-resistance (EC50)
of the cells bearing #305 RNAwas not as high as that of original
#305, this finding suggests that acquisition of IFNα-resistance
of these cells was due to genetic alteration of the replicon RNA.
We investigated the phosphorylation status of Stat-1 by
stimulation of IFNα in these cells. As shown in Fig. 7, phos-
phorylation of Stat-1 in #305/Huh-7 (lane 2) was suppressed
compared with that in Huh-9-13/Huh-7 (lane 4), suggesting that
the IFNα-resistant HCV replicon derived from #305 is respon-
sible for acquisition of the decreasing response to Stat-1 phos-
phorylation stimulated by IFNα.
Direct sequencing analysis of IFNα-resistant replicons
Nucleotide sequences in the NS region of each resistant clone
were determined by RT-PCR direct sequencing. Sites of mutation
that were detected only in IFNα-resistant replicons are shown by
arrowheads and numbers (N-terminus of NS3 was denoted as
1027 based on the numbering of the complete polyprotein of the
isolate), together with conversion of amino acids by arrows
(Fig. 8). Although synonymous mutations are clustered in NS3
and the C-terminal region of NS5A, there were no common
mutations among these resistant clones. Moreover, no mutations
located at the positions as in IFNα-resistant replicons established
by Namba et al. (2004) and Sumpter et al. (2004) were found in
the present study. Mutations in the ISDR of NS5Awere reportedFig. 9. Expression of NS protein (NS4B) (A) and β-actin (B) was confirmed in
‘cured cells’ by western blot analysis. Huh-7 cells with JTP-71892 as well as
replicon cells (Huh-9-13 and #305) were analyzed likewise.to play an important role in outcome of IFN treatment to patients
with genotype 1b of HCV in Japan (Enomoto et al., 1996);
however, the amino acid sequence of ISDRwas preserved among
these replicon cell lines in our experiments.
Characterization of ‘cured cells’ obtained by IFNα-resistant
HCV replicon cells
To clarify the role of HCV replicon RNA in resistance to
IFNα, the replicon cells (Huh-9-13 and #305) were treated with
JTP-71892 (1 μM) for more than 1 month to establish ‘cured
cells’, as described in Materials and methods. JTP-71892 is a
JTK-109-derivative synthesized in our laboratory, which has a
potent inhibitory effect on HCV replication (Hirashima et al.,
2006). The amounts of HCV replicon RNA in both replicon-
bearing cell types were decreased less than what could be
detected by quantitative RT-PCR, while the amounts of GAPDH
mRNA used as a control did not show any difference (data not
shown). The representative HCV NS protein, NS4B, was not
detected in the ‘cured cells’ (Fig. 9).
The phosphorylation status of Stat-1 was then analyzed in
these cells. The Stat-1 phosphorylation (Tyr701) by IFNα sti-
mulation has restored remarkably in ‘cured cells’ (derived from
both Huh-9-13 and #305) (Fig. 10). There was no obvious
difference in the extent of Stat-1 phosphorylation by JTP-71892
treatment in Huh-7, indicating that restoration of Stat-1 phos-
phorylation was not due to JTP-71892. There was no clear dif-
ference in the amount of non-phosphorylated Stat-1 and β-actin
expression by the IFNα stimulation or JTP-71892 treatment
among these cell clones. These results suggest that HCV repli-
con RNA contributes to IFNα-resistance through impairment of
phosphorylation of Stat-1, at least in part.
Discussion
We cultured HCV replicon cells in the presence of 10 and
30 IU/mL IFNα to isolate IFNα-resistant clones. Four different
resistant clones with differing sensitivities to IFNα were iso-
lated. The sensitivity for IFNα attenuated more than 100-fold in
the #305 replicon, which was isolated in the presence of 30 IU/
mL of IFNα and showed the most remarkable resistance in our
study.
We analyzed the appearance of G418-resistant cells, #305/
Huh-7, obtained by transfection of total RNA from the IFNα-
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the absence of IFNα, as shown in Fig. 1. IFNα sensitivities of
the Huh-7 cells transduced with HCV replicon RNA of #305
cells were about 6-fold lower than those transfected with total
RNA of original replicon cells (Huh-9-13), in coincident with a
reduction of Stat-1 phosphorylation. However, #305/Huh-7
conferred a lesser extent of IFNα-resistance compared with that
of parental #305 (Figs. 2 and 6). Although some factors other
than HCV replicon RNA itself may participate in acquisition of
IFNα-resistance in #305 cells, these results suggest that replicon
RNA derived from #305 was significantly involved in regu-
lation of IFNα signaling. The ‘cured cells’, from which HCV
genomic RNA was removed from IFNα-resistant replicon cell
line (#305) after treatment with 1 μM of JTP-71892, a potent
HCV replication inhibitor, resulted in restoration of IFNα sig-
naling to parental Huh-7. This finding suggests that HCV
replicon RNA plays important roles in suppression of Stat-1
function. Moreover, this effect is dependent on mutation of
HCV replicon RNA.
Mutations of amino acids were clustered throughout the
whole region of NS3 and the C-terminus of NS5A in the IFNα-
resistant replicon RNAs; however, there were no common amino
acid mutations among the clones. This result may suggest the
possibility that a change of plural functions participates in the
acquisition of resistance. Whereas we did not identify common
mutations, four amino acid mutations, K1406E, I1472F, I1694T,
and S2386P, in NS3/4A and NS5Awere shown to be common in
#8, #9, and #305. In particular, the mutation at S2386P in NS5A
located near regionV3, one of the important prediction factors of
the outcome in clinical IFN therapy (Nousbaum et al., 2000;
Puig-Basagoiti et al., 2005), is found in #9 and #305. The
nucleotide sequence of ISDR region was preserved between
original replicon and IFNα-resistant replicons.
Concerning the mutations in NS5A region of #305, we
established 3 chimeric replicon cell clones harboring Huh-9-13
replicon that was substituted with NS5A coding region derived
from #305, which was selected by G418 in the absence of IFNα.
These cell clones showed reduction of IFNα sensitivity (EC50)
as 20 to 30 times as those of normal replicon cell (Huh-9-13).
Although chimeric replicons harboring #305 NS5A showed
lesser extent of IFNα-resistance than that of #305 replicon cell,
NS5A of #305 plays an important role in acquisition of IFNα-
resistance in the replicon cell (data not shown).
Naka et al. (2005) reported that nonsense mutations and
deletions of type I IFN receptor genes (IFNAR1, IFNAR2c)
were found in certain clones of replicon cells that gained IFNα-
resistance. However, we did not detect any such mutation or
deletion in either of these genes in this work. Furthermore, we
were not able to obtain resistant phenotype by IFN treatment at
high concentrations of more than 1000 IU/mL.
In #305, among other IFNα-resistant clones, substantial
amount of slow migrating form of NS5A was observed. From
previous reports (Asabe et al., 1997, Ide et al., 1997; Kaneko et al.,
1994; Kim et al., 1999; Reed et al., 1997, 1998; Tanji et al., 1995),
it is supposed that this form is hyper-phosphorylatedNS5Awith 58
KD. Hyper-phosphorylated form of NS5A (p58) negatively
participates in replication of HCV RNA in replicon cells (Appelet al., 2005; Evans et al., 2004; Huang et al., 2006; Neddermann
et al., 2004). However, the quantity of basal HCV replication in
#305 was almost the same as in other replicon cells, including
Huh-9-13. Thus, it is likely that the hyper-phosphorylation of
NS5A does not contribute to suppression of replication of HCV
replicon. Rather, it may be related to a potent IFNα-resistance in
#305 via un-identified mechanisms. Further studies are needed to
clarify the role of hyper-phosphorylatedNS5A in IFNα-resistance.
Concerning effects of NS5A on IFN signaling, it was re-
ported that transiently- or stably-transfected NS5A inhibits IFN-
stimulated Stat-1 phosphorylation and transactivation of ISRE
in hepatocyte-derived cell lines, including Huh-7 cell (Gong
et al., 2007; Lan et al., 2007). These authors also suggested the
interaction of NS5A with Stat-1. Although these evaluation
methods were different from that of our replicon system, they
lend additional credibility to the suggestion that NS5A plays an
important role in regulation of IFN signaling via inhibition of
Stat-1 phosphorylation.
Stat-1 phosphorylation by IFNα stimulationwas suppressed in
IFNα-resistant replicon cells. The degree of suppression of Stat-1
phosphorylation was related to the sensitivity of IFNα in IFNα-
resistant replicons (Fig. 5A). Moreover, the decrease of Stat-1
phosphorylation in #305 cells maintained in the absence of IFNα
for 4 weeks was almost same level as that maintained in the
presence of IFNα, suggesting that IFNα pressure did not induce a
negative feedback (i.e. leading to the degradation of IFN receptor)
loop in our experimental system. In contrast, Stat-1 phosphoryla-
tion was not changed significantly in parental Huh-7 cells that
were maintained in the presence of IFNα compared with that
maintained in the absence of IFNα (Fig. 5B), suggesting that Stat-
1 phosphorylation in the parental Huh-7 cells was not affected
with IFNα pressure and that the alteration of HCV replicon con-
fers the IFNα-resistance. Stat-1 phosphorylation was also
suppressed in the Huh-7 cells transfected with total RNA from
IFNα-resistant replicon (Fig. 7). Moreover, the ‘cured cells’
showed a restoration of Stat-1 phosphorylation (Fig. 10). These
observations suggest that IFNα-resistance in IFNα-resistant re-
plicon cells depends on a change in Stat-1 phosphorylation, at
least in part. For unknown reasons, we could not detect phos-
phorylation of Stat-2 (Tyr689), Stat-3 (Tyr705) (Sarcar et al.,
2004; Zhu et al., 2005), JAK-1 (Tyr1022), or Tyk-2 (Tyr1054) in
these cells. Concerning these proteins in the replicon cells, further
investigation is needed to understand their roles in acquisition of
IFNα-resistance.
Although the underlying mechanism of acquisition of IFNα-
resistance gained by HCV replicon RNA remains unclear,
clarification of detailed analysis of the role of Stat-1 in regard to




Huh-9-13 cells harboring HCV subgenomic (NS3-3′X) re-
plicon and parental Huh-7 cells were purchased from ReBLikon
GmbH. Cells were cultured in Dulbecco's modified Eagle's
430 T. Noguchi et al. / Virology 375 (2008) 424–432medium (DMEM) supplemented with 10% fetal bovine serum.
To Huh-9-13 cells, 1 mg/mL of G418 (Geneticin; Invitrogen), a
selective marker for replicated HCV subgenome was added.
IFN treatment
Huh-9-13 cells were seeded in a 75-cm2 flask at a density of
3×105 cells/flask. Twenty-four hours after cell seeding, human
IFNα (Sumiferon®300; Dainippon Sumitomo Pharma) was
added so that the final concentration in medium was 10 IU/mL.
Control cells were cultured in medium with no other additional
substances. Cell passages were performed approximately every
7 days and the cells were cultured for approximately 1 month in
the presence of IFNα (10 IU/mL). After decreases in sensitivity to
IFNα were confirmed in the IFNα-treated groups by quantitative
RT-PCR, IFNα-resistant cell phenotypes were further cultured for
about 1 month in the presence of 30 IU/mL IFNα, and sensitivity
to IFNα was then also measured in these cells. The cells cultured
in the presence of 10 or 30 IU/mL of IFNα were cloned by a
limiting dilutionmethod using 96-well plates: cells were seeded at
1 cell/well and cultured in medium containing 10 IU/mL IFNα.
After culture for about two to three weeks, survival and growth of
cloned cells were confirmed, and then colonies were isolated and
added to 48-well plates containing the test substance in 500 μL of
culture medium per well. The proliferated cells in the 48-well
plates were transferred to 6-well plates, and these were further put
into 75-cm2 cell culture flasks for subculture. Thereafter, sub-
culture passage was performed approximately every 7 days.
Cloning and subculture were performed in the presence of IFNα.
Measurement of IFN-sensitivity (quantitative analysis of HCV
replicon and GAPDH mRNA)
IFN-sensitivity of IFNα-treated replicon cells was measured
by quantitative RT-PCR. Cells (1×104 cells/well) were seeded in
96-well plates in the presence of 0, 0.1, 0.3, 1, 3, 10, 30, 100, 300,
or 1000 IU/mL of IFNα. Forty-eight hours after cultivation with
IFNα, the cells were harvested to extract total RNA using a total
RNA extraction kit (RNeasy® 96; Qiagen) in accordance with the
instruction manual. Quantification of HCV replicon RNA in the
prepared RNAwas performed using TaqMan® EZ RT-PCR Core
Reagent (ABI) using a sequence detector under the following
conditions: sense-primer: 5′-CGGGAGAGCCATAGTGG-3′
(130-S17; Greiner), antisense-primer: 5′-AGTACCACAAG-
GCCTTTCG-3′ (290-R19; Greiner), probe: 5′(FAM)-CTGCG-
GAACCGGTGAGTACAC (TAMRA)-3′ (148-S21FT; TaKaRa)
(Takeuchi et al., 1999), RT-PCR reaction conditions: 50 °C,
2 min→60 °C, 30 min→95 °C, 5 min→45 cycles×(95 °C,
20 s→62 °C, 1 min). The number of copies in the samples was
determined using a standard curve calibrated with 104 to 108
copies of synthesized HCV RNA standards encoding from 5′
terminus to E2 region, and recorded as amount of HCV RNA.
Direct sequencing analysis of HCV replicon RNA
Nucleotide sequences of HCVrepliconRNAwere analyzed by
direct sequencing method. The NS region of total RNA extractedfrom IFNα-resistant replicon clones was divided into four frag-
ments and amplified using an RT-PCR kit (ReverTra Dash®;
TOYOBO). Four primers (HCV-NS-1RV: 5′-ATAGCACT-
CGCACAGAACCGA-3′; Greiner, HCV-NS-2RV: 5′-GGAAC-
CGTTTTTCACATGTCC-3′; Greiner, HCV-NS-3RV: 5′-
ATGTGGTTAACGGCCTTGCT-3′; Greiner, HCV-NS-4RV:
5′-TCATCGGTTGGGGAGTAGATAGA-3′; Greiner) were
used for reverse transcription (RT). For polymerase chain reaction
(PCR), another four primers (HCV-NS-1FW: 5′-ATGGCGCC-
TATTACGGCCTA-3′; Greiner, HCV-NS-2FW: 5′-TGTTC-
GATTCCTCGGTTCTGT-3′; Greiner, HCV-NS-3FW: 5′-
CCCCTTCTTCTCATGTCAACG-3′; Greiner, HCV-NS-4 FW:
5′-GGAACCTATCCAGCAAGCCC-3′; Greiner) were used in
addition to the primers for RT.
RT and PCR reactions were conducted in accordance with
the instruction manual provided with the kit. RT reaction was
conducted at 42 °C, 20 min, and the reaction mixtures were then
heated to 99 °C, 5 min. The PCR reaction was performed for
30 cycles under the following conditions: 98 °C, 10 s; 60 °C,
2 s; then 74 °C, 90 s.
Sequencing was performed using a BigDye Terminator Cycle
Sequencing Ready Reaction Kit (ABI). One μL of amplified RT-
PCR product for each clone was purified using QIAquick Gel
Extraction kit (Qiagen) and the sequence primers were used to
prepare each of the reaction solutions in accordance with the
manufacturer's procedure. Twenty μL of each solution was
allowed to react for 25 cycles under the conditions: 96 °C, 10 s;
50 °C, 5 s; 60 °C, 4 min; then 72 °C, 7 min. The solutions were
then purified by Dye EX 2.0 (Qiagen) in accordance with the
instruction manual. After that, the samples were applied for
sequencing analysis using an ABI PRISM 3100 genetic analyzer
(ABI).
The NS region (5952 bp, 1984 amino acids) in sequenced
samples underwent gene analysis using Vector NTI analysis
software (Invitrogen). In a comparison of deduced amino acid
sequences based on nucleotide sequences among the four IFNα-
resistant replicon clones and original replicons, the NS regions
were compared to that of the original replicon clone to identify
mutations. The amino acid sequence of the original replicon
cells was included among the materials provided with the Huh-
9-13 cell line product from ReBLikon GmbH.
Reporter gene analysis
We attempted to clarify IFNα transactivation in IFNα-
resistant replicons. Firefly luciferase fused gene with three
repeats of an ISG15-type IFN-stimulated responsive element
(ISRE) was used as a reporter construct (pISRE/Luc). HCV
replicon cells or Huh-7 cells (3×105 cells/well) were seeded on
a 60-mm plate in the absence of IFNα. Eight hours after cell
seeding, the reporter construct (3 μg) was transfected using
FuGENE6 (Roche) as a transfection reagent, following the
instruction manual. The transfected cells were cultured further
12 to 14 h, and then the cells (1×104 cells) were inoculated on a
96-well plate and cultured for 24 h with or without 1000 IU/mL
of IFNα. The luciferase activity was measured by adding Steady
Glo® to the cells using TopCount (Packard).
431T. Noguchi et al. / Virology 375 (2008) 424–432Western blot analysis
The cell lysates were prepared in Laemmli buffer (BIO-
RAD) and subjected to SDS-2/15% gradient PAGE and
transferred onto nitrocellulose membranes. To detect expression
of HCV NS proteins, antibodies against NS3, NS4B, NS5A,
and NS5B were used. Anti-β-actin antibody (Sigma) was also
used for detection of β-actin as an internal control.
To investigate the phosphorylation of Stat-1 at Tyr701 in HCV
replicon cells and its parental Huh-7 cells, the cells were cultured
in the medium containing 500 IU/mL of IFNα for 30 min. After
cell lysates were prepared as previously described, western blot
analysis was performed using an anti-phospho-Stat-1 (Tyr701)
antibody (Cell Signaling Technology) or an anti-Stat-1 antibody
(BD Transduction Laboratories). Immunocomplexes were de-
tected by visualization using enhanced chemiluminescence
(Amersham Biosciences).
Transfection of total RNA derived from replicon cells to naive
Huh-7
Total RNA (5 μg) extracted from HCV replicon cells was
transfected to Huh-7 cells using DMRIE-C transfection reagents,
in accordance with the instruction manuals provided with the
reagents. The transfected cells were cultured in the absence of
IFNα and selected with 1000 μg/mL of G418 for 4 weeks. Drug-
resistant cells were collected and reactivity to IFNαwasmeasured
as described in previous section.
Elimination of HCV replicon RNA from replicon cells (Isolation
of ‘cured’ replicon)
To remove HCV replicon RNA from replicon cells, HCV
replicon cells were treated (‘cured’) with HCV RNA-dependent
RNA polymerase NS5B inhibitor, JTP-71892, JTK-109-
derivatives synthesized in our laboratory (Hirashima et al.,
2006; Ishida et al., 2006). The replicon cells (5×104 cells) were
inoculated on a 60-mm plate and further cultured in the pre-
sence of the compound (1 μM) for about 4 weeks. The cell
culture was performed in the absence of G418, to prevent su-
rvival of the compound-resistant clones. Medium was ex-
changed with fresh medium containing the compound twice per
week. The finding that 1 μM of JTP-71892 does not exhibit any
toxicity or growth inhibition in long-term culture had been
previously confirmed.
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